Cardiology research at ResMed

ResMed is a global pioneer and leader in respiratory care. With our programme to research clinical areas related to sleep-disordered breathing, we aim to further develop our in-depth knowledge on sleep and respiratory disorders. That’s why we support and actively engage in research initiatives related to cardiology.

Explore our research initiatives for cardiology below.

SCHLA-HF

SCHLA-HF is a major multi-centre screening registry exploring the prevalence and prediction of sleep-disordered breathing and heart failure. It is the largest database of its kind, with 10,000 patients enrolled in 213 cardiology centres.

CAT HF

CAT HF is a multi-centre, randomised and controlled trial aiming to assess the effects of ASV in patients after a hospitalisation for acute decompensated heart failure.  It began in multiple US sites in September 2013. Results are expected in 2016.

FACE

The FACE study is a French prospective, multicentre, observational cohort that will provide long-term data on morbidity and mortality of heart failure patients using ASV. So far over 270 patients have been enrolled by 30 centres, with a target of 300 chronic HF patients at the end of December 2014.

For clinical literature on sleep apnoea and cardiology, consult our dedicated ResMed page